Meeting
2020 Genitourinary Cancers Symposium
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS).
Authors
Guillermo de Velasco
Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
Guillermo de Velasco , Álvaro Ruiz-Granados , Oscar Reig , Francesco Massari , Miguel Angel Climent Duran , Elena Verzoni , Jeffrey Graham , Roberto Llarena , Michele De Tursi , Frede Donskov , Clara Iglesias , Hardev S. Pandha , Xavier Garcia del Muro , Giuseppe Procopio , Stephane Oudard , Daniel Castellano , Laurence Albiges
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 701)
Abstract #
701
Poster Bd #
G21
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Advanced pulmonary carcinoid (APC): 20-year experience at Johns Hopkins (JH).
First Author: Patrick M. Forde
Poster
2022 ASCO Genitourinary Cancers Symposium
Systemic therapy in patients with metastatic Xp11.2 translocation renal cell carcinoma.
First Author: Xieqiao Yan
Poster
2018 Genitourinary Cancers Symposium
Patients perspectives on adjuvant therapy in renal cell carcinoma.
First Author: Dena Battle
Poster
2014 Genitourinary Cancers Symposium
Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.
First Author: Matteo Santoni